BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Extra | Dec 6, 2016
Clinical News

Kite, Novartis update CAR T timelines at ASH

Kite Pharma Inc. (NASDAQ:KITE) and Novartis AG (NYSE:NVS; SIX:NOVN) each provided updates on their lead chimeric antigen receptor (CAR) T cell therapies targeting CD19 . Updates for both programs, which are nearing FDA review, occurred at...
Items per page:
1 - 2 of 2